{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "status": "retrieved", "company": "Egetis Therapeutics", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:34:44Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q1 2026", "category": "Interimsrapport", "date": "2026-04-29", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b6eed573445c5007fad22497e9ea6e15a&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "Q1 2026 Report SE Final 29Apr26.pdf", "url": "https://attachment.news.eu.nasdaq.com/a6942a777fa930bf7ba2a66e9c6e7d709", "final_url": "https://attachment.news.eu.nasdaq.com/a6942a777fa930bf7ba2a66e9c6e7d709", "filename": "Q1_2026_Report_SE_Final_29Apr26.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2026-q1\\Q1_2026_Report_SE_Final_29Apr26.pdf", "content_type": "application/pdf", "size": 640178, "sha256": "ff9f5cc745ae70cf8c049a2abd6c76b101978569d7298748622e6f886ff4f589", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2026-q1\\Q1_2026_Report_SE_Final_29Apr26.pdf", "filename": "Q1_2026_Report_SE_Final_29Apr26.pdf", "extension": ".pdf", "size": 640178, "sha256": "ff9f5cc745ae70cf8c049a2abd6c76b101978569d7298748622e6f886ff4f589", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2026-q1\\extracted\\Q1_2026_Report_SE_Final_29Apr26\\Q1_2026_Report_SE_Final_29Apr26.txt", "text_chars": 46392, "metadata": { "page_count": 18, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2026-q1\\extracted\\Q1_2026_Report_SE_Final_29Apr26\\Q1_2026_Report_SE_Final_29Apr26.extraction.json" } } ], "announcement_id": "1437930", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:34:55Z", "company": "Egetis Therapeutics AB", "title": "Publicering av Egetis Therapeutics årsredovisning för 2025", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-03-24", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bd422734e05445b3d94aa01527b8e5ec3&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "SE Egetis Arsredovisning 2025 Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/a206b29851971e83a5e68d755cca5175a", "final_url": "https://attachment.news.eu.nasdaq.com/a206b29851971e83a5e68d755cca5175a", "filename": "SE_Egetis_Arsredovisning_2025_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-annual\\SE_Egetis_Arsredovisning_2025_Final.pdf", "content_type": "application/pdf", "size": 11443646, "sha256": "206190893364d309d49e76354c86f46872e1ddc1eda7ff77c2d41d92821021f9", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-annual\\SE_Egetis_Arsredovisning_2025_Final.pdf", "filename": "SE_Egetis_Arsredovisning_2025_Final.pdf", "extension": ".pdf", "size": 11443646, "sha256": "206190893364d309d49e76354c86f46872e1ddc1eda7ff77c2d41d92821021f9", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-annual\\extracted\\SE_Egetis_Arsredovisning_2025_Final\\SE_Egetis_Arsredovisning_2025_Final.txt", "text_chars": 315393, "metadata": { "page_count": 103, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-annual\\extracted\\SE_Egetis_Arsredovisning_2025_Final\\SE_Egetis_Arsredovisning_2025_Final.extraction.json" } } ], "announcement_id": "1428467", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:34:58Z", "company": "Egetis Therapeutics AB", "title": "Bokslutskommuniké januari-december 2025", "category": "Bokslutskommuniké", "date": "2026-02-26", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b44b80c3eb35069e5d3ef27619cf43fbf&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "Q4 2025 Report SE Final 26Feb26.pdf", "url": "https://attachment.news.eu.nasdaq.com/afb4ad5faeb596fcdd65881be25fbee53", "final_url": "https://attachment.news.eu.nasdaq.com/afb4ad5faeb596fcdd65881be25fbee53", "filename": "Q4_2025_Report_SE_Final_26Feb26.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q4\\Q4_2025_Report_SE_Final_26Feb26.pdf", "content_type": "application/pdf", "size": 958917, "sha256": "1bde4c42b0bb53c1c079966ee502f2bfe91ba95d1277103e83b2ac60b2c45362", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q4\\Q4_2025_Report_SE_Final_26Feb26.pdf", "filename": "Q4_2025_Report_SE_Final_26Feb26.pdf", "extension": ".pdf", "size": 958917, "sha256": "1bde4c42b0bb53c1c079966ee502f2bfe91ba95d1277103e83b2ac60b2c45362", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q4\\extracted\\Q4_2025_Report_SE_Final_26Feb26\\Q4_2025_Report_SE_Final_26Feb26.txt", "text_chars": 49800, "metadata": { "page_count": 19, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q4\\extracted\\Q4_2025_Report_SE_Final_26Feb26\\Q4_2025_Report_SE_Final_26Feb26.extraction.json" } } ], "announcement_id": "1422635", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:35:03Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q3 2025", "category": "Interimsrapport", "date": "2025-11-25", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b2bc7bcb707477cbbca001cd7f5bbfe7f&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "Q3 2025 Report SE Final 251125.pdf", "url": "https://attachment.news.eu.nasdaq.com/abb89c7e3bfb497221a55896c76316fd4", "final_url": "https://attachment.news.eu.nasdaq.com/abb89c7e3bfb497221a55896c76316fd4", "filename": "Q3_2025_Report_SE_Final_251125.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q3\\Q3_2025_Report_SE_Final_251125.pdf", "content_type": "application/pdf", "size": 779464, "sha256": "b49416f6b530d87e6fa92f0709ba4418aa8f662bf4d10ce866e085ae271edc8f", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q3\\Q3_2025_Report_SE_Final_251125.pdf", "filename": "Q3_2025_Report_SE_Final_251125.pdf", "extension": ".pdf", "size": 779464, "sha256": "b49416f6b530d87e6fa92f0709ba4418aa8f662bf4d10ce866e085ae271edc8f", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q3\\extracted\\Q3_2025_Report_SE_Final_251125\\Q3_2025_Report_SE_Final_251125.txt", "text_chars": 50087, "metadata": { "page_count": 20, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q3\\extracted\\Q3_2025_Report_SE_Final_251125\\Q3_2025_Report_SE_Final_251125.extraction.json" } } ], "announcement_id": "1402507", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:35:09Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q2 2025", "category": "Halvårsrapport", "date": "2025-08-21", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bdc02099a782352223cdc8a80791bb306&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "Q2 2025 Report SE 21Aug25 Final2.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac44f8c6ae3726c1abdc80e5151a80988", "final_url": "https://attachment.news.eu.nasdaq.com/ac44f8c6ae3726c1abdc80e5151a80988", "filename": "Q2_2025_Report_SE_21Aug25_Final2.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q2\\Q2_2025_Report_SE_21Aug25_Final2.pdf", "content_type": "application/pdf", "size": 3931510, "sha256": "1c00dfb9aa39bd12a0d6a12a54d34af3bd191f6215f3fadd5c09216425e94ed0", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q2\\Q2_2025_Report_SE_21Aug25_Final2.pdf", "filename": "Q2_2025_Report_SE_21Aug25_Final2.pdf", "extension": ".pdf", "size": 3931510, "sha256": "1c00dfb9aa39bd12a0d6a12a54d34af3bd191f6215f3fadd5c09216425e94ed0", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q2\\extracted\\Q2_2025_Report_SE_21Aug25_Final2\\Q2_2025_Report_SE_21Aug25_Final2.txt", "text_chars": 9423, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q2\\extracted\\Q2_2025_Report_SE_21Aug25_Final2\\Q2_2025_Report_SE_21Aug25_Final2.extraction.json" } } ], "announcement_id": "1384370", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:35:26Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q1 2025", "category": "Interimsrapport", "date": "2025-04-30", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b04407352577b944f1db775fbba6cc0a5&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "Q1 2025 Report SE 30Apr25 Final2.pdf", "url": "https://attachment.news.eu.nasdaq.com/aa1bc658ddda1a1d6cf03e3d41bc34bfd", "final_url": "https://attachment.news.eu.nasdaq.com/aa1bc658ddda1a1d6cf03e3d41bc34bfd", "filename": "Q1_2025_Report_SE_30Apr25_Final2.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\Q1_2025_Report_SE_30Apr25_Final2.pdf", "content_type": "application/pdf", "size": 3889984, "sha256": "871a604ecdb9a247807b4e13d1d4103875dbdf1d35e3325acdaed35e470bfa3b", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\Q1_2025_Report_SE_30Apr25_Final2.pdf", "filename": "Q1_2025_Report_SE_30Apr25_Final2.pdf", "extension": ".pdf", "size": 3889984, "sha256": "871a604ecdb9a247807b4e13d1d4103875dbdf1d35e3325acdaed35e470bfa3b", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\extracted\\Q1_2025_Report_SE_30Apr25_Final2\\Q1_2025_Report_SE_30Apr25_Final2.txt", "text_chars": 12060, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\extracted\\Q1_2025_Report_SE_30Apr25_Final2\\Q1_2025_Report_SE_30Apr25_Final2.extraction.json" } }, { "label": "Egetis årsredovisning 2024", "url": "https://storage.mfn.se/6c145720-d2d9-4d4e-a1d2-0c306524c482/se-egetis-arsredovisning-2024-final-11apr24.pdf", "final_url": "https://storage.mfn.se/6c145720-d2d9-4d4e-a1d2-0c306524c482/se-egetis-arsredovisning-2024-final-11apr24.pdf", "filename": "se-egetis-arsredovisning-2024-final-11apr24.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\se-egetis-arsredovisning-2024-final-11apr24.pdf", "content_type": "application/pdf", "size": 5686570, "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\se-egetis-arsredovisning-2024-final-11apr24.pdf", "filename": "se-egetis-arsredovisning-2024-final-11apr24.pdf", "extension": ".pdf", "size": 5686570, "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\extracted\\se-egetis-arsredovisning-2024-final-11apr24\\se-egetis-arsredovisning-2024-final-11apr24.txt", "text_chars": 322374, "metadata": { "page_count": 104, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2025-q1\\extracted\\se-egetis-arsredovisning-2024-final-11apr24\\se-egetis-arsredovisning-2024-final-11apr24.extraction.json" } } ], "announcement_id": "1359479", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:35:36Z", "company": "Egetis Therapeutics AB", "title": "Publicering av Egetis Therapeutics årsredovisning för 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-04-11", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b5e86dbf640e2107ef0195a10490f2570&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "SE Egetis Arsredovisning 2024 Final 11Apr24.pdf", "url": "https://attachment.news.eu.nasdaq.com/a46c706f2daf09ea8e3384d4049251d6f", "final_url": "https://attachment.news.eu.nasdaq.com/a46c706f2daf09ea8e3384d4049251d6f", "filename": "SE_Egetis_Arsredovisning_2024_Final_11Apr24.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-annual\\SE_Egetis_Arsredovisning_2024_Final_11Apr24.pdf", "content_type": "application/pdf", "size": 5686570, "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-annual\\SE_Egetis_Arsredovisning_2024_Final_11Apr24.pdf", "filename": "SE_Egetis_Arsredovisning_2024_Final_11Apr24.pdf", "extension": ".pdf", "size": 5686570, "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-annual\\extracted\\SE_Egetis_Arsredovisning_2024_Final_11Apr24\\SE_Egetis_Arsredovisning_2024_Final_11Apr24.txt", "text_chars": 322374, "metadata": { "page_count": 104, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-annual\\extracted\\SE_Egetis_Arsredovisning_2024_Final_11Apr24\\SE_Egetis_Arsredovisning_2024_Final_11Apr24.extraction.json" } } ], "announcement_id": "1355567", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:35:39Z", "company": "Egetis Therapeutics AB", "title": "Bokslutskommuniké januari-december 2024", "category": "Bokslutskommuniké", "date": "2025-02-26", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b54c8861ab69dd5eb6b82cb4c09c9ecfd&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "Q4 2024 Report SE 26Feb25 FINAL.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae9ee14b96c878a9a47db936acdbb5aa3", "final_url": "https://attachment.news.eu.nasdaq.com/ae9ee14b96c878a9a47db936acdbb5aa3", "filename": "Q4_2024_Report_SE_26Feb25_FINAL.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q4\\Q4_2024_Report_SE_26Feb25_FINAL.pdf", "content_type": "application/pdf", "size": 752855, "sha256": "7a4a10a1d1c6c88068236b0ffa80bd9650e4cae88f80b5c1a62e4ba8e0e5f6d3", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q4\\Q4_2024_Report_SE_26Feb25_FINAL.pdf", "filename": "Q4_2024_Report_SE_26Feb25_FINAL.pdf", "extension": ".pdf", "size": 752855, "sha256": "7a4a10a1d1c6c88068236b0ffa80bd9650e4cae88f80b5c1a62e4ba8e0e5f6d3", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q4\\extracted\\Q4_2024_Report_SE_26Feb25_FINAL\\Q4_2024_Report_SE_26Feb25_FINAL.txt", "text_chars": 60074, "metadata": { "page_count": 25, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q4\\extracted\\Q4_2024_Report_SE_26Feb25_FINAL\\Q4_2024_Report_SE_26Feb25_FINAL.extraction.json" } } ], "announcement_id": "1345242", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:35:45Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q3 2024", "category": "Interimsrapport", "date": "2024-11-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3079030691d8cfcfff1aa18663986305&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "Q3 2024 Report SE 08Nov24 Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/a00e566ae0ea10c2f34e55f9ae3dbfc07", "final_url": "https://attachment.news.eu.nasdaq.com/a00e566ae0ea10c2f34e55f9ae3dbfc07", "filename": "Q3_2024_Report_SE_08Nov24_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q3\\Q3_2024_Report_SE_08Nov24_Final.pdf", "content_type": "application/pdf", "size": 734556, "sha256": "a1a8d360bc3da5e4da946ec8c2702fde4f5eeb447605dd895ed6f93c7a7383f1", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q3\\Q3_2024_Report_SE_08Nov24_Final.pdf", "filename": "Q3_2024_Report_SE_08Nov24_Final.pdf", "extension": ".pdf", "size": 734556, "sha256": "a1a8d360bc3da5e4da946ec8c2702fde4f5eeb447605dd895ed6f93c7a7383f1", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q3\\extracted\\Q3_2024_Report_SE_08Nov24_Final\\Q3_2024_Report_SE_08Nov24_Final.txt", "text_chars": 63859, "metadata": { "page_count": 26, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q3\\extracted\\Q3_2024_Report_SE_08Nov24_Final\\Q3_2024_Report_SE_08Nov24_Final.extraction.json" } } ], "announcement_id": "1326627", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:35:51Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q2 2024", "category": "Halvårsrapport", "date": "2024-08-22", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bf3afba6a33edcdc6e6188bc8f6cfd633&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "Q2 2024 Report SE 240822 Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad971c0227867ee160499400f812e4bc1", "final_url": "https://attachment.news.eu.nasdaq.com/ad971c0227867ee160499400f812e4bc1", "filename": "Q2_2024_Report_SE_240822_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q2\\Q2_2024_Report_SE_240822_Final.pdf", "content_type": "application/pdf", "size": 4800621, "sha256": "51e1b382f5a02633c6cfe88c874df8987bf950c55b1a47f1ff17d3eedb18e663", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q2\\Q2_2024_Report_SE_240822_Final.pdf", "filename": "Q2_2024_Report_SE_240822_Final.pdf", "extension": ".pdf", "size": 4800621, "sha256": "51e1b382f5a02633c6cfe88c874df8987bf950c55b1a47f1ff17d3eedb18e663", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q2\\extracted\\Q2_2024_Report_SE_240822_Final\\Q2_2024_Report_SE_240822_Final.txt", "text_chars": 11615, "metadata": { "page_count": 27, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q2\\extracted\\Q2_2024_Report_SE_240822_Final\\Q2_2024_Report_SE_240822_Final.extraction.json" } } ], "announcement_id": "1312095", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:35:57Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q1 2024", "category": "Interimsrapport", "date": "2024-05-03", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b5d81534397dc40acd5a145f1bab09c3c&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "Q1 2024 Report SE 240502 Final3.pdf", "url": "https://attachment.news.eu.nasdaq.com/abd668147eaa3e410da42161261df85bc", "final_url": "https://attachment.news.eu.nasdaq.com/abd668147eaa3e410da42161261df85bc", "filename": "Q1_2024_Report_SE_240502_Final3.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q1\\Q1_2024_Report_SE_240502_Final3.pdf", "content_type": "application/pdf", "size": 4354125, "sha256": "579b9bc37fc30053cc5539be29354a48a33bfbc0341d9e37ee3c4d79e11eaaae", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q1\\Q1_2024_Report_SE_240502_Final3.pdf", "filename": "Q1_2024_Report_SE_240502_Final3.pdf", "extension": ".pdf", "size": 4354125, "sha256": "579b9bc37fc30053cc5539be29354a48a33bfbc0341d9e37ee3c4d79e11eaaae", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q1\\extracted\\Q1_2024_Report_SE_240502_Final3\\Q1_2024_Report_SE_240502_Final3.txt", "text_chars": 18247, "metadata": { "page_count": 26, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2024-q1\\extracted\\Q1_2024_Report_SE_240502_Final3\\Q1_2024_Report_SE_240502_Final3.extraction.json" } } ], "announcement_id": "1292896", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:36:08Z", "company": "Egetis Therapeutics AB", "title": "Publicering av Egetis Therapeutics årsredovisning för 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-04-15", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bf825d303bbb3f339d86185713acda286&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "SE Egetis Arsredovisning 2023 15apr Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/af3cbeb2a13b2252df08cedc14f66f84e", "final_url": "https://attachment.news.eu.nasdaq.com/af3cbeb2a13b2252df08cedc14f66f84e", "filename": "SE_Egetis_Arsredovisning_2023_15apr_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-annual\\SE_Egetis_Arsredovisning_2023_15apr_Final.pdf", "content_type": "application/pdf", "size": 5302920, "sha256": "c13ece608fcfbaf3d8bdc4f7c9d4b18ab9bdbcd5a2816c389909574d7516621b", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-annual\\SE_Egetis_Arsredovisning_2023_15apr_Final.pdf", "filename": "SE_Egetis_Arsredovisning_2023_15apr_Final.pdf", "extension": ".pdf", "size": 5302920, "sha256": "c13ece608fcfbaf3d8bdc4f7c9d4b18ab9bdbcd5a2816c389909574d7516621b", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-annual\\extracted\\SE_Egetis_Arsredovisning_2023_15apr_Final\\SE_Egetis_Arsredovisning_2023_15apr_Final.txt", "text_chars": 318947, "metadata": { "page_count": 100, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-annual\\extracted\\SE_Egetis_Arsredovisning_2023_15apr_Final\\SE_Egetis_Arsredovisning_2023_15apr_Final.extraction.json" } } ], "announcement_id": "1287934", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:36:12Z", "company": "Egetis Therapeutics AB", "title": "Bokslutskommuniké januari-december 2023", "category": "Bokslutskommuniké", "date": "2024-02-22", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=bda8425e5dd15751763854e309cc2a802&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "Q4 2023 Report SE 22Feb24 Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/a12a7619ddbbcdd6dbc09b8b68c4559b6", "final_url": "https://attachment.news.eu.nasdaq.com/a12a7619ddbbcdd6dbc09b8b68c4559b6", "filename": "Q4_2023_Report_SE_22Feb24_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q4\\Q4_2023_Report_SE_22Feb24_Final.pdf", "content_type": "application/pdf", "size": 5097667, "sha256": "c74b0310aa944a883fbfde5f82b17babc92c1a2544b19825afe7c951fa796187", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q4\\Q4_2023_Report_SE_22Feb24_Final.pdf", "filename": "Q4_2023_Report_SE_22Feb24_Final.pdf", "extension": ".pdf", "size": 5097667, "sha256": "c74b0310aa944a883fbfde5f82b17babc92c1a2544b19825afe7c951fa796187", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q4\\extracted\\Q4_2023_Report_SE_22Feb24_Final\\Q4_2023_Report_SE_22Feb24_Final.txt", "text_chars": 12027, "metadata": { "page_count": 27, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q4\\extracted\\Q4_2023_Report_SE_22Feb24_Final\\Q4_2023_Report_SE_22Feb24_Final.extraction.json" } } ], "announcement_id": "1276507", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:36:17Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q3 2023", "category": "Interimsrapport", "date": "2023-11-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b4b37225e0947f3a95bc7db73dc9508a9&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "Q3 2023 Report SE 231108 Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/af10655b0f42a9aca5c888135b38d3696", "final_url": "https://attachment.news.eu.nasdaq.com/af10655b0f42a9aca5c888135b38d3696", "filename": "Q3_2023_Report_SE_231108_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q3\\Q3_2023_Report_SE_231108_Final.pdf", "content_type": "application/pdf", "size": 4156255, "sha256": "6b974f7a141056849b25d4455bd5a97735ff5a76dd998261d1efdb488ac1bd86", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q3\\Q3_2023_Report_SE_231108_Final.pdf", "filename": "Q3_2023_Report_SE_231108_Final.pdf", "extension": ".pdf", "size": 4156255, "sha256": "6b974f7a141056849b25d4455bd5a97735ff5a76dd998261d1efdb488ac1bd86", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q3\\extracted\\Q3_2023_Report_SE_231108_Final\\Q3_2023_Report_SE_231108_Final.txt", "text_chars": 14617, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q3\\extracted\\Q3_2023_Report_SE_231108_Final\\Q3_2023_Report_SE_231108_Final.extraction.json" } } ], "announcement_id": "1257838", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:36:22Z", "company": "Egetis Therapeutics AB", "title": "Kvartalsrapport Q2 2023", "category": "Halvårsrapport", "date": "2023-08-22", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b29970ae3290eb0fee17334f1634fc4f4&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "Q2 2023 Report SE 2023 08 22 Final.pdf", "url": "https://attachment.news.eu.nasdaq.com/a7bfb1997a92a6956a70d8d6fec6bdca2", "final_url": "https://attachment.news.eu.nasdaq.com/a7bfb1997a92a6956a70d8d6fec6bdca2", "filename": "Q2_2023_Report_SE_2023_08_22_Final.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q2\\Q2_2023_Report_SE_2023_08_22_Final.pdf", "content_type": "application/pdf", "size": 4293308, "sha256": "bb0886b68a2e034010940ab25a0ffc98402fc63c1f316c59cfb58a860ff10a0c", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q2\\Q2_2023_Report_SE_2023_08_22_Final.pdf", "filename": "Q2_2023_Report_SE_2023_08_22_Final.pdf", "extension": ".pdf", "size": 4293308, "sha256": "bb0886b68a2e034010940ab25a0ffc98402fc63c1f316c59cfb58a860ff10a0c", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q2\\extracted\\Q2_2023_Report_SE_2023_08_22_Final\\Q2_2023_Report_SE_2023_08_22_Final.txt", "text_chars": 12420, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q2\\extracted\\Q2_2023_Report_SE_2023_08_22_Final\\Q2_2023_Report_SE_2023_08_22_Final.extraction.json" } } ], "announcement_id": "1243661", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T10:36:26Z", "company": "Egetis Therapeutics AB", "title": "Delårsrapport januari-mars 2023", "category": "Interimsrapport", "date": "2023-04-26", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b8eda6e67ac908da1643016b7ac20eb8f&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "Q1 2023 Report SE 26Apr23 FINAL.pdf", "url": "https://attachment.news.eu.nasdaq.com/a54a3c90b056400d051dbf7b09b8f0182", "final_url": "https://attachment.news.eu.nasdaq.com/a54a3c90b056400d051dbf7b09b8f0182", "filename": "Q1_2023_Report_SE_26Apr23_FINAL.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q1\\Q1_2023_Report_SE_26Apr23_FINAL.pdf", "content_type": "application/pdf", "size": 3952205, "sha256": "7bd65deddf5154ea59d06116f0426bab167e1bec38b054a309421d852aabbe0c", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q1\\Q1_2023_Report_SE_26Apr23_FINAL.pdf", "filename": "Q1_2023_Report_SE_26Apr23_FINAL.pdf", "extension": ".pdf", "size": 3952205, "sha256": "7bd65deddf5154ea59d06116f0426bab167e1bec38b054a309421d852aabbe0c", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q1\\extracted\\Q1_2023_Report_SE_26Apr23_FINAL\\Q1_2023_Report_SE_26Apr23_FINAL.txt", "text_chars": 11347, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\egetis-therapeutics\\nasdaq-reports\\reports\\2023-q1\\extracted\\Q1_2023_Report_SE_26Apr23_FINAL\\Q1_2023_Report_SE_26Apr23_FINAL.extraction.json" } } ], "announcement_id": "1222438", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "90d54e2f7d6a61fb1bbfdcc4e4f03d95251bc78008e2453ac4b6a71fd000ac16" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "635e800497364312a304bf29350dd84bc90982ae637014d78476a8b9d53c3166" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 200, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 78, "new_rows": 78, "total_count": null, "from_cache": false, "body_sha256": "1b478b8b525e193a000cc5ddb0c50c5fd7dd194a38bf8cb6f34f777904d6dc64" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=278&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 278, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "a85d7522fff0fd106017f4136b2d43c08a87350f5132a533dac14dfb327307eb" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 1, "new_rows": 1, "total_count": null, "from_cache": false, "body_sha256": "fa271fc4dbd4fdf5a8e99dcb540b205bf9d5d4a472d1a1546aee23c5bce1f79c" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=1&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 1, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "b0baeec2e2e08d034f3e6378faf59c9d544cb3d1cd4e64d2dae5360d27808f71" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "31877cc81ff8d778dea57322e8a1b41d3dabd9a79d18c98b068c7f9ae8ed06d3" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "7f90da84870055b38caca3500b5c5cca6021b8b4ae229670206aa6758c9f6a72" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 200, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 31, "new_rows": 31, "total_count": null, "from_cache": false, "body_sha256": "cd1e01693548c267ec21b7da792ae99ccbded464bd700f7e6e8250e1c17de4bc" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=231&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 231, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "5a7eebf17bd628568c96a990c04696cf40a7e6530f891f500b244aad81794e86" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Egetis+Therapeutics&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Egetis Therapeutics", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "f5c8bedd1257bce3d40b895a576e3ae329d320655a88f2abde9296a7a9e60889" } ], "identity": { "slug": "egtx", "instrument_id": "TX868732", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/egtx?id=TX868732" }, "transport": "ordinary-http", "browser_used": false, "query_text": "Egetis Therapeutics", "retrieved_at": "2026-08-04T10:36:27Z" }